Welcome to our dedicated page for Legend Biotech SEC filings (Ticker: LEGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Legend Biotech Corporation (NASDAQ: LEGN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a foreign private issuer. Legend Biotech files annual reports on Form 20‑F and frequent current reports on Form 6‑K, which together outline its financial performance, cell therapy pipeline, and key business developments.
In these filings, Legend Biotech presents unaudited interim condensed consolidated financial statements, including statements of profit or loss, financial position, changes in equity, and cash flows. Investors can review details on license revenue, collaboration revenue related to CARVYKTI® (ciltacabtagene autoleucel; cilta‑cel), research and development expenses, selling and distribution expenses, and collaboration funding arrangements. Management’s Discussion and Analysis (MD&A), often attached as exhibits to Form 6‑K, provides narrative context around revenue drivers, cost trends, and liquidity.
Filings also capture clinical and regulatory milestones. Recent 6‑Ks incorporate press releases on CARTITUDE‑1, CARTITUDE‑4, and CARTITUDE‑6 study updates, FDA and European Commission label changes for CARVYKTI, and early data from programs such as LUCAR‑G39D, LB2102, and LB1908. Additional 6‑Ks describe agreements with Janssen for component and product supply, preliminary sales figures for CARVYKTI, and participation in major scientific and investor conferences.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy 6‑K and 20‑F filings, helping users quickly identify information on revenue composition, cell therapy pipeline status, collaboration structures, and risk disclosures. Real‑time ingestion of EDGAR updates ensures that new Legend Biotech filings, including any Form 6‑K related to financial results or material agreements, appear promptly.
Users can also monitor equity and compensation-related disclosures via Legend Biotech’s registration statements on Form S‑8, as referenced in its 6‑K reports, and review how these interact with share‑based compensation expenses reported in the financial statements. While Legend Biotech does not file Forms 3, 4, and 5 as a U.S. domestic issuer would, this page centralizes its available SEC reporting so investors can follow the company’s development as a global cell therapy business.
Legend Biotech Corporation (NASDAQ: LEGN) has filed a Form 144 indicating a proposed insider sale of American Depositary Shares (ADS). According to the notice, the reporting shareholder plans to sell 11,810 ADS through Fidelity Brokerage Services on or about 24 June 2025. At the reference market price used in the filing, the transaction is valued at roughly $408,600. The sale represents an immaterial 0.003 % of the company’s 367.3 million ADS outstanding, suggesting limited direct impact on the public float.
The securities to be sold stem from restricted stock that vested on 20 June 2025 as part of the filer’s compensation package. Form 144 data also disclose prior sales by the same individual—4,064 ADS on 25 March 2025 for $143,371 and 6,548 ADS on 1 May 2025 for $226,233. Cumulatively, the filer has disposed of 10,612 ADS (≈$369,604) in the past three months, and the new planned trade will bring three-month total dispositions to 22,422 ADS worth about $778,000.
The filing includes the standard representation that the seller is unaware of any undisclosed material adverse information. No details about the filer’s position, trading plan status, or reason for the sale are provided. While insider sales can raise governance questions, the small size relative to capitalization and the routine vesting-related nature of the shares suggest limited financial significance for shareholders.
Legend Biotech Corporation (LEGN) – Form 144 filing
The filing, marked as LIVE, notifies the SEC of a proposed Rule 144 sale of 307 American Depositary Shares (ADS), valued at approximately $10,551.59. Fidelity Brokerage Services LLC is listed as broker, and the sale is expected to occur on or about 24 June 2025 on NASDAQ.
The ADS were acquired on 20 June 2025 through the vesting of restricted stock awarded as compensation. Outstanding ADS total 367,298,315; therefore, the planned disposition represents less than 0.0001 % of shares outstanding, indicating an immaterial effect on float or control.
The filer, identified in prior activity as Corazon Sanders, previously sold an identical lot of 307 ADS on 25 March 2025 for gross proceeds of $11,153.31. No relationship to the issuer, 10b5-1 plan details, or additional insider roles are disclosed. The signer attests to possessing no undisclosed material adverse information.